[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE315654T1 - Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen - Google Patents

Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen

Info

Publication number
ATE315654T1
ATE315654T1 AT96940870T AT96940870T ATE315654T1 AT E315654 T1 ATE315654 T1 AT E315654T1 AT 96940870 T AT96940870 T AT 96940870T AT 96940870 T AT96940870 T AT 96940870T AT E315654 T1 ATE315654 T1 AT E315654T1
Authority
AT
Austria
Prior art keywords
aur
polypeptides
diagnosis
treatment
diseases associated
Prior art date
Application number
AT96940870T
Other languages
English (en)
Inventor
Gregory D Plowman
Kevin G Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE315654(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE315654T1 publication Critical patent/ATE315654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96940870T 1995-12-18 1996-11-25 Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen ATE315654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14

Publications (1)

Publication Number Publication Date
ATE315654T1 true ATE315654T1 (de) 2006-02-15

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940870T ATE315654T1 (de) 1995-12-18 1996-11-25 Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen

Country Status (15)

Country Link
US (2) US5962312A (de)
EP (2) EP1655369A1 (de)
JP (1) JP3944241B2 (de)
KR (1) KR100459052B1 (de)
AT (1) ATE315654T1 (de)
AU (1) AU716330B2 (de)
CA (1) CA2239692C (de)
DE (1) DE69635740T2 (de)
DK (1) DK0868519T3 (de)
ES (1) ES2255715T3 (de)
IL (1) IL124728A (de)
NO (1) NO323646B1 (de)
NZ (1) NZ323795A (de)
PT (1) PT868519E (de)
WO (1) WO1997022702A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
WO1999009160A1 (fr) * 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Proteines de regulation de cycle cellulaire
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
SK3822002A3 (en) * 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
WO2003012046A2 (en) * 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
CA2480635A1 (en) * 2002-03-28 2003-10-09 Allen D. Delaney Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
EP1546182B1 (de) * 2002-09-11 2011-01-05 Genentech, Inc. Zusammensetzungen und verfahren für die tumordiagnose und behandlung
CA2506066A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
BRPI0317717B8 (pt) 2002-12-24 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e uso de um composto
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1597391B1 (de) * 2003-02-20 2008-10-29 Genomic Health, Inc. Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
EP1636380A2 (de) * 2003-05-30 2006-03-22 Genomic Health, Inc. Genexpressionsmarker zur reaktion auf egfr-inhibitor-arzneistoffe
JP4680898B2 (ja) 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005040396A2 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING
EP1694686A1 (de) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinaseinhibitoren
WO2005064019A2 (en) * 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
EP1763514A2 (de) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl-substituierte pyrimidindiaminverbindungen und deren verwendung
US20050282208A1 (en) * 2004-06-18 2005-12-22 Cytokinetics, Inc. Cellular phenotype
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
ATE550440T1 (de) * 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
AU2005304824B2 (en) 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
BRPI0608178A2 (pt) 2005-04-14 2009-11-17 Hoffmann La Roche derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007079445A2 (en) * 2006-01-03 2007-07-12 Sunesis Pharmaceuticals, Inc. Aurora expression constructs
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
WO1994023039A1 (en) * 1993-04-07 1994-10-13 The Institute Of Cancer Research: Royal Cancer Hospital Methods for screening of substances for therapeutic activity and yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
ES2255715T3 (es) 2006-07-01
US5972676A (en) 1999-10-26
US5962312A (en) 1999-10-05
EP0868519B1 (de) 2006-01-11
NO323646B1 (no) 2007-06-18
DE69635740T2 (de) 2006-09-14
IL124728A (en) 2007-06-03
AU716330B2 (en) 2000-02-24
JP3944241B2 (ja) 2007-07-11
WO1997022702A1 (en) 1997-06-26
EP1655369A1 (de) 2006-05-10
IL124728A0 (en) 1999-01-26
EP0868519A1 (de) 1998-10-07
JP2000502895A (ja) 2000-03-14
NO982794L (no) 1998-08-18
KR100459052B1 (ko) 2005-01-15
CA2239692A1 (en) 1997-06-26
KR20000064437A (ko) 2000-11-06
DE69635740D1 (de) 2006-04-06
AU1082697A (en) 1997-07-14
NO982794D0 (no) 1998-06-17
NZ323795A (en) 2000-01-28
PT868519E (pt) 2006-05-31
CA2239692C (en) 2008-12-16
DK0868519T3 (da) 2006-05-08

Similar Documents

Publication Publication Date Title
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE69926731D1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
DE69334246D1 (de) Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69807878D1 (de) Erkennung und Modulierung von IAPS und NAIP zur Diagnose und Behandlung von proliferativen Erkrankungen
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
LU91015I2 (fr) Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
DK1015477T3 (da) 32 humane sekreterede proteiner
EP0538401A4 (en) Novel receptor-type phosphotyrosine phosphatase
ATE179712T1 (de) Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen
DE3751893D1 (de) Polypeptid und dessen Herstellung
ATE284955T1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
DE69327167D1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0868519

Country of ref document: EP